Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Octant Inc. is currently navigating 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are being reviewed by 3 distinct examiners, indicating that no two pending actions are currently assigned to the same individual. Furthermore, these cases are situated within 2 distinct art units. The busiest examiner for the portfolio is M Franco G Salvoza, who holds 1 busiest examiner pending action. Since the total number of pending office actions is 3 and there are 3 distinct examiners, the workload is distributed among the assigned staff.
Practitioners can expect that the prosecution of these Biotechnology & Pharmaceuticals applications will involve distinct perspectives from each of the 3 examiners across the 2 art units. This lack of examiner overlap means that a success or failure with one examiner may not directly influence the others, although the shared 2 distinct art units might lead to some commonality in the prior art cited. With 3 pending office actions and 3 distinct examiners, the legal team has the opportunity to test different arguments across the portfolio. The role of M Franco G Salvoza as the busiest examiner is shared, as they only handle 1 busiest examiner pending action. This decentralized examiner structure within the Biotechnology & Pharmaceuticals sector requires the practitioner to be adaptable to the specific preferences of each of the 3 distinct examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §103 only | 1 (33%) |
| §112 only | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SALVOZA, M FRANCO G | 1 | 68.2% | +30.6% |
| PAK, MICHAEL D | 1 | 58.6% | +29.9% |
| STAVROU, CONSTANTINA E | 1 | 42.4% | +35.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18275199 | SYSTEMS AND METHODS FOR MEASURING CELL SIGNALING PROTEIN ACTIVITY | PAK, MICHAEL D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17532791 | TRANSCRIPTIONAL RELAY SYSTEM | STAVROU, CONSTANTINA E | 14d |
| 18885280 | PATHOGEN DIAGNOSTIC TEST | SALVOZA, M FRANCO G | — |
| 18275199 | SYSTEMS AND METHODS FOR MEASURING CELL SIGNALING PROTEIN ACTIVITY | PAK, MICHAEL D | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18885280 | PATHOGEN DIAGNOSTIC TEST | SALVOZA, M FRANCO G | — | §112 | Non-Final OA | — | Pending | Sep 13, 2024 |
| 18275199 | SYSTEMS AND METHODS FOR MEASURING CELL SIGNALING PROTEIN ACTIVITY | PAK, MICHAEL D | 1644 | §101§102§112Other | Non-Final OA | — | Pending | Jul 31, 2023 |
| 17532791 | TRANSCRIPTIONAL RELAY SYSTEM | STAVROU, CONSTANTINA E | 1632 | §103 | Final Rejection | 14d | Pending | Nov 22, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOctant Inc. has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
M Franco G Salvoza has the most, with 1 of Octant Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
